271 related articles for article (PubMed ID: 25474358)
1. HSP70 domain II of Mycobacterium tuberculosis modulates immune response and protective potential of F1 and LcrV antigens of Yersinia pestis in a mouse model.
Batra L; Verma SK; Nagar DP; Saxena N; Pathak P; Pant SC; Tuteja U
PLoS Negl Trop Dis; 2014 Dec; 8(12):e3322. PubMed ID: 25474358
[TBL] [Abstract][Full Text] [Related]
2. Vaccine Potential of a Recombinant Bivalent Fusion Protein LcrV-HSP70 Against Plague and Yersiniosis.
Gupta A; Narayan B; Kumar S; Verma SK
Front Immunol; 2020; 11():988. PubMed ID: 32595634
[TBL] [Abstract][Full Text] [Related]
3. A Recombinant Trivalent Fusion Protein F1-LcrV-HSP70(II) Augments Humoral and Cellular Immune Responses and Imparts Full Protection against Yersinia pestis.
Verma SK; Batra L; Tuteja U
Front Microbiol; 2016; 7():1053. PubMed ID: 27458447
[TBL] [Abstract][Full Text] [Related]
4. Intranasal delivery of a protein subunit vaccine using a Tobacco Mosaic Virus platform protects against pneumonic plague.
Arnaboldi PM; Sambir M; D'Arco C; Peters LA; Seegers JF; Mayer L; McCormick AA; Dattwyler RJ
Vaccine; 2016 Nov; 34(47):5768-5776. PubMed ID: 27745954
[TBL] [Abstract][Full Text] [Related]
5. Characterization of the protective immune response to Yersinia pseudotuberculosis infection in mice vaccinated with an LcrV-secreting strain of Lactococcus lactis.
Daniel C; Titecat M; Poiret S; Cayet D; Boutillier D; Simonet M; Sirard JC; Lemaître N; Sebbane F
Vaccine; 2016 Nov; 34(47):5762-5767. PubMed ID: 27742220
[TBL] [Abstract][Full Text] [Related]
6. LcrV delivered via type III secretion system of live attenuated Yersinia pseudotuberculosis enhances immunogenicity against pneumonic plague.
Sun W; Sanapala S; Henderson JC; Sam S; Olinzock J; Trent MS; Curtiss R
Infect Immun; 2014 Oct; 82(10):4390-404. PubMed ID: 25114109
[TBL] [Abstract][Full Text] [Related]
7. Targeting of LcrV virulence protein from Yersinia pestis to dendritic cells protects mice against pneumonic plague.
Do Y; Koh H; Park CG; Dudziak D; Seo P; Mehandru S; Choi JH; Cheong C; Park S; Perlin DS; Powell BS; Steinman RM
Eur J Immunol; 2010 Oct; 40(10):2791-6. PubMed ID: 20812236
[TBL] [Abstract][Full Text] [Related]
8. A Recombinant Attenuated
Singh AK; Curtiss R; Sun W
Infect Immun; 2019 Oct; 87(10):. PubMed ID: 31331960
[TBL] [Abstract][Full Text] [Related]
9. TNFα and IFNγ contribute to F1/LcrV-targeted immune defense in mouse models of fully virulent pneumonic plague.
Lin JS; Park S; Adamovicz JJ; Hill J; Bliska JB; Cote CK; Perlin DS; Amemiya K; Smiley ST
Vaccine; 2010 Dec; 29(2):357-62. PubMed ID: 20840834
[TBL] [Abstract][Full Text] [Related]
10. Humoral and cellular immune correlates of protection against bubonic plague by a live Yersinia pseudotuberculosis vaccine.
Demeure CE; Derbise A; Guillas C; Gerke C; Cauchemez S; Carniel E; Pizarro-Cerdá J
Vaccine; 2019 Jan; 37(1):123-129. PubMed ID: 30467064
[TBL] [Abstract][Full Text] [Related]
11. Comparison of mouse, guinea pig and rabbit models for evaluation of plague subunit vaccine F1+rV270.
Qi Z; Zhou L; Zhang Q; Ren L; Dai R; Wu B; Wang T; Zhu Z; Yang Y; Cui B; Wang Z; Wang H; Qiu Y; Guo Z; Yang R; Wang X
Vaccine; 2010 Feb; 28(6):1655-60. PubMed ID: 20079562
[TBL] [Abstract][Full Text] [Related]
12. A comparison of immunogenicity and protective immunity against experimental plague by intranasal and/or combined with oral immunization of mice with attenuated Salmonella serovar Typhimurium expressing secreted Yersinia pestis F1 and V antigen.
Liu WT; Hsu HL; Liang CC; Chuang CC; Lin HC; Liu YT
FEMS Immunol Med Microbiol; 2007 Oct; 51(1):58-69. PubMed ID: 17640293
[TBL] [Abstract][Full Text] [Related]
13. Yersinia pestis caf1 variants and the limits of plague vaccine protection.
Quenee LE; Cornelius CA; Ciletti NA; Elli D; Schneewind O
Infect Immun; 2008 May; 76(5):2025-36. PubMed ID: 18347051
[TBL] [Abstract][Full Text] [Related]
14. T cells play an essential role in anti-F1 mediated rapid protection against bubonic plague.
Levy Y; Flashner Y; Tidhar A; Zauberman A; Aftalion M; Lazar S; Gur D; Shafferman A; Mamroud E
Vaccine; 2011 Sep; 29(40):6866-73. PubMed ID: 21803090
[TBL] [Abstract][Full Text] [Related]
15. Expression of an F1/V fusion protein in attenuated Salmonella typhimurium and protection of mice against plague.
Leary SE; Griffin KF; Garmory HS; Williamson ED; Titball RW
Microb Pathog; 1997 Sep; 23(3):167-79. PubMed ID: 9281474
[TBL] [Abstract][Full Text] [Related]
16. Yersinia pestis YadC: a novel vaccine candidate against plague.
Murphy BS; Wulff CR; Garvy BA; Straley SC
Adv Exp Med Biol; 2007; 603():400-14. PubMed ID: 17966436
[TBL] [Abstract][Full Text] [Related]
17. Involvement of CD8+ T cell-mediated immune responses in LcrV DNA vaccine induced protection against lethal Yersinia pestis challenge.
Wang S; Goguen JD; Li F; Lu S
Vaccine; 2011 Sep; 29(39):6802-9. PubMed ID: 21199697
[TBL] [Abstract][Full Text] [Related]
18. A single component two-valent LcrV-F1 vaccine protects non-human primates against pneumonic plague.
Chichester JA; Musiychuk K; Farrance CE; Mett V; Lyons J; Mett V; Yusibov V
Vaccine; 2009 May; 27(25-26):3471-4. PubMed ID: 19200825
[TBL] [Abstract][Full Text] [Related]
19. A nasal interleukin-12 DNA vaccine coexpressing Yersinia pestis F1-V fusion protein confers protection against pneumonic plague.
Yamanaka H; Hoyt T; Yang X; Golden S; Bosio CM; Crist K; Becker T; Maddaloni M; Pascual DW
Infect Immun; 2008 Oct; 76(10):4564-73. PubMed ID: 18694965
[TBL] [Abstract][Full Text] [Related]
20. A Replication-Defective Human Type 5 Adenovirus-Based Trivalent Vaccine Confers Complete Protection against Plague in Mice and Nonhuman Primates.
Sha J; Kirtley ML; Klages C; Erova TE; Telepnev M; Ponnusamy D; Fitts EC; Baze WB; Sivasubramani SK; Lawrence WS; Patrikeev I; Peel JE; Andersson JA; Kozlova EV; Tiner BL; Peterson JW; McWilliams D; Patel S; Rothe E; Motin VL; Chopra AK
Clin Vaccine Immunol; 2016 Jul; 23(7):586-600. PubMed ID: 27170642
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
